# Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL

> **NCT07638787** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Large B-cell Lymphoma

## Interventions

- **DRUG:** Polatuzumab Vedotin
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Prednisone
- **DRUG:** Sonrotoclax

## Key facts

- **NCT ID:** NCT07638787
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2027-09-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07638787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07638787, "Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07638787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*